[go: up one dir, main page]

SG11201700901SA - Anti-trem2 antibodies and methods of use thereof - Google Patents

Anti-trem2 antibodies and methods of use thereof

Info

Publication number
SG11201700901SA
SG11201700901SA SG11201700901SA SG11201700901SA SG11201700901SA SG 11201700901S A SG11201700901S A SG 11201700901SA SG 11201700901S A SG11201700901S A SG 11201700901SA SG 11201700901S A SG11201700901S A SG 11201700901SA SG 11201700901S A SG11201700901S A SG 11201700901SA
Authority
SG
Singapore
Prior art keywords
methods
trem2 antibodies
trem2
antibodies
Prior art date
Application number
SG11201700901SA
Inventor
Kate Monroe
Tina Schwabe
Francesca Avogadri-Connors
Ilaria Tassi
Helen Lam
Arnon Rosenthal
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55264791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201700901S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alector Llc filed Critical Alector Llc
Publication of SG11201700901SA publication Critical patent/SG11201700901SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201700901SA 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of use thereof SG11201700901SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462035336P 2014-08-08 2014-08-08
US201562135122P 2015-03-18 2015-03-18
US201562135110P 2015-03-18 2015-03-18
PCT/US2015/044396 WO2016023019A2 (en) 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201700901SA true SG11201700901SA (en) 2017-03-30

Family

ID=55264791

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913611QA SG10201913611QA (en) 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of use thereof
SG11201700901SA SG11201700901SA (en) 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913611QA SG10201913611QA (en) 2014-08-08 2015-08-08 Anti-trem2 antibodies and methods of use thereof

Country Status (11)

Country Link
US (4) US20170240631A1 (en)
EP (2) EP3177322A4 (en)
JP (4) JP6669749B2 (en)
CN (1) CN107106679B (en)
AU (2) AU2015300787A1 (en)
CA (2) CA2955086A1 (en)
EA (1) EA201790342A1 (en)
IL (2) IL279606B (en)
MX (2) MX2017001531A (en)
SG (2) SG10201913611QA (en)
WO (1) WO2016023019A2 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
US20190330335A1 (en) * 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
CA3010224A1 (en) 2016-01-22 2017-07-27 Merck Sharp & Dohme Corp. Anti-coagulation factor xi antibodies
EA201892716A1 (en) 2016-06-14 2019-05-31 Мерк Шарп И Доум Корп. Antibody to Coagulation Factor XI
AU2017300040A1 (en) * 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
US11779642B2 (en) 2016-12-09 2023-10-10 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
JOP20190243A1 (en) * 2017-04-12 2019-10-13 Medimmune Llc Treatment of asthma with anti-tslp antibody
CN108727489B (en) * 2017-04-19 2021-02-09 广州市第八人民医院 Monoclonal antibody ZK2C2 and application
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
EP3652749A4 (en) 2017-07-14 2021-03-24 The Regents of The University of California PROCEDURE FOR PREDICTING THE RISK OF TRANSPLANT REJECTION
DK3601358T5 (en) * 2017-08-03 2024-09-02 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEREOF
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
KR102709597B1 (en) * 2017-10-03 2024-09-26 프리베일 테라퓨틱스, 인크. Gene therapies for lysosomal disorders
KR102860409B1 (en) * 2017-12-12 2025-09-16 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 Anti-TREM2 antibodies and related methods
US11746150B2 (en) 2017-12-19 2023-09-05 Surrozen Operating, Inc. Anti-LRP5/6 antibodies and methods of use
CN118271444A (en) 2017-12-19 2024-07-02 瑟罗泽恩奥普瑞汀公司 WNT replacement molecules and uses thereof
JP7418332B2 (en) 2017-12-19 2024-01-19 スロゼン オペレーティング， インコーポレイテッド Anti-Frizzled antibody and usage method
US11440957B2 (en) * 2017-12-29 2022-09-13 Alector Llc Anti-TMEM106B antibodies and methods of use thereof
BR112020014929A2 (en) * 2018-01-23 2020-12-08 Nextcure, Inc. PHARMACEUTICAL COMPOSITION, METHODS FOR INCREASING, REDUCING, INTENSIFYING OR INDUCING AN IMMUNE RESPONSE IN AN INDIVIDUAL, MOLECULE, MONOCLONAL ANTIBODY OR FRAGMENT OF BINDING THE ANTIGEN OF THE SAME, NUCLEUS ANTIGEN ANTIGEN, ANTICORUS , ANTI-B7H4 ANTIBODY OR ANTIGEN BINDING FRAGMENT OF THE SAME, ANTI-B7H4 ANTIBODY LIGHT AND HEAVY CHAINS, AND LIGHT AND HEAVY ANTIBODY CHAINS
JP7337099B2 (en) * 2018-05-25 2023-09-01 アレクトル エルエルシー ANTI-SIRPA ANTIBODY AND USES THEREOF
EA202190183A1 (en) 2018-07-27 2021-05-18 Алектор Ллс ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
KR20210057113A (en) 2018-09-11 2021-05-20 워싱턴 유니버시티 Anti-TREM-2 agonist antibody
UY38407A (en) * 2018-10-15 2020-05-29 Novartis Ag TREM2 STABILIZING ANTIBODIES
KR102156165B1 (en) * 2018-10-29 2020-09-15 재단법인대구경북과학기술원 Monoclonal antibody with specificity for human TREM2 protein, hybridoma cell line producing the same and use thereof
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3122725A1 (en) * 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
CA3120875A1 (en) * 2018-12-11 2020-06-18 Pionyr Immunotherapeutics, Inc. Methods of using anti-trem2 antibodies
CN109646668B (en) * 2019-01-04 2019-10-18 厦门大学 Use of a polypeptide for the preparation of drugs for preventing and treating Alzheimer's disease
EP3927743A1 (en) * 2019-02-20 2021-12-29 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
WO2020194317A1 (en) * 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CN110320368A (en) * 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） Diagnostic kit based on TREM2 and its application on diagnosis of Parkinson disease product
CA3145291A1 (en) * 2019-07-05 2021-01-14 University Of Florida Research Foundation, Incorporated Methods for treating ran protein-associated neurological diseases
EP3999543A1 (en) * 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
US11655303B2 (en) * 2019-09-16 2023-05-23 Surface Oncology, Inc. Anti-CD39 antibody compositions and methods
PH12022551228A1 (en) 2019-11-22 2023-06-14 Lilly Co Eli Trem2 antibodies and uses thereof
CN111000978B (en) * 2019-11-22 2023-03-10 中山大学附属第五医院 Application of TLT-2 in preparation of medicine for treating tuberculosis
WO2021113655A1 (en) 2019-12-05 2021-06-10 Alector Llc Methods of use of anti-trem2 antibodies
KR20220131246A (en) * 2020-01-13 2022-09-27 데날리 테라퓨틱스 인크. Anti-TREM2 antibodies and methods of use thereof
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Methods of treating cancer
US20230183340A1 (en) * 2020-02-26 2023-06-15 Washington University Compositions and Methods for Reducing Resistance to or Enhancing Immunotherapy
CR20230069A (en) * 2020-08-05 2023-08-16 Vigil Neuroscience Inc Treatment of diseases related to colony-stimulating factor 1 receptor dysfunction using trem2 agonists
CN112526143B (en) * 2020-12-03 2021-08-03 中山大学附属第五医院 Application of myeloid cell trigger receptor 2 as a diagnostic or therapeutic target for novel coronavirus pneumonia
CN115141271B (en) * 2021-01-31 2024-06-11 中南大学湘雅医院 Novel coronavirus monoclonal antibody XY7 and application thereof
KR20240134116A (en) * 2021-11-22 2024-09-06 비질 뉴로사이언스 인코포레이티드 Anti-TREM2 antibodies and uses thereof
MX2024007263A (en) 2021-12-17 2024-08-09 Denali Therapeutics Inc MODIFICATION OF POLYPEPTIDES, LIBRARIES AND MODIFIED CD98 HEAVY CHAIN AND TRANSFERRIN RECEPTOR-BINDING POLYPEPTIDES.
EP4455275A1 (en) * 2021-12-22 2024-10-30 Kagoshima University Method for producing macrophages, differentiation inducing agent, differentiation induction kit, method for culturing macrophages, agent for promoting macrophage propagation, kit for promoting macrophage proliferation, method for macrophage proliferation, and macrophages
WO2023150724A2 (en) * 2022-02-04 2023-08-10 Sorrento Therapeutics, Inc. Antigen binding proteins that bind b7-h3
IL314666A (en) * 2022-02-17 2024-09-01 Anokion Sa Anti-asgr1 polypeptides and methods of use for immune tolerance
CN114395034B (en) * 2022-03-24 2022-08-05 中国科学院微生物研究所 Human antibody for efficiently neutralizing novel coronavirus and application thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
EP4611630A1 (en) * 2022-11-01 2025-09-10 Vigil Neuroscience, Inc. Anti-trem2 antibody and uses thereof
EP4658684A1 (en) 2023-01-30 2025-12-10 ISAR Bioscience GmbH Human anti-trem2 antibody for treating neurodegenerative disorders
WO2024250809A1 (en) * 2023-06-08 2024-12-12 成都优洛生物科技有限公司 Anti-trem2 fully human antibody or antigen-binding fragment thereof, and use thereof
WO2024253424A1 (en) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 Humanized antibody specifically binding to human trem2 protein and use thereof
WO2024262577A1 (en) * 2023-06-21 2024-12-26 国立大学法人 鹿児島大学 Method for producing human macrophage, differentiation-inducing agent, differentiation-inducing kit, method for inducing differentiation of human macrophage, proliferation-promoting agent for human macrophage, kit for promoting proliferation of human macrophage, method for proliferating human macrophage, and human macrophage
WO2025015713A1 (en) * 2023-07-19 2025-01-23 成都优洛生物科技有限公司 Anti-trem2 humanized antibody, antigen binding fragment thereof, and use thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
TW202515919A (en) 2023-09-01 2025-04-16 比利時商艾托斯比利時公司 Anti-trem2 antibodies and methods of use
WO2025072253A1 (en) * 2023-09-25 2025-04-03 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12269882B1 (en) 2023-09-25 2025-04-08 Kelonia Therapeutics, Inc. Antigen binding polypeptides
US12403194B2 (en) 2023-09-25 2025-09-02 Kelonia Therapeutics, Inc. Compositions for treating cancer
CN119529096A (en) * 2023-12-21 2025-02-28 华润生物医药有限公司 Anti-TREM2 antibodies and uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0617706B1 (en) 1991-11-25 2001-10-17 Enzon, Inc. Multivalent antigen-binding proteins
DE69334255D1 (en) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker for cancer and biosynthetic binding protein for it
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
JPH08500017A (en) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド Bispecific immune adhesin
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
AU7378096A (en) 1995-09-28 1997-04-17 Alexion Pharmaceuticals, Inc. Porcine cell interaction proteins
DE19544393A1 (en) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistic herbicidal mixtures
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
BR9813365A (en) 1997-12-05 2004-06-15 Scripps Research Inst Method for Production and Humanization of a Mouse Monoclonal Antibody
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
CA2331386A1 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (en) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy PROCESS FOR REGULATING THE TRANSCRIPTION OF FOREIGN GENES IN THE PRESENCE OF NITROGEN
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20090081199A1 (en) 2001-03-20 2009-03-26 Bioxell S.P.A. Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
JP2004073182A (en) 2002-05-24 2004-03-11 Takeda Chem Ind Ltd Insulin resistance-improving agent
EP1508340A4 (en) 2002-05-24 2009-07-01 Takeda Pharmaceutical INSULIN RESISTANCE ENHANCING AGENTS
CA2502413A1 (en) 2002-11-01 2004-05-21 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
JP2006515747A (en) 2002-11-01 2006-06-08 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
WO2004074506A2 (en) 2003-02-13 2004-09-02 Mergen Ltd Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers
MX2007008017A (en) 2004-12-31 2007-09-12 Genentech Inc Polypeptides that bind br3 and uses thereof.
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
HUE066795T2 (en) 2006-03-15 2024-09-28 Alexion Pharma Inc Treatment of patients with paroxysmal nocturnal haemoglobinuria with a complement inhibitor
DE202006007499U1 (en) * 2006-05-11 2007-01-11 Osaka University Use of a composition that inhibits plexin-A1-DAP12 interaction for the treatment of inflammatory, autoimmune or bone resorption disorders
WO2008042261A2 (en) 2006-09-28 2008-04-10 Elusys Therapeutics, Inc. Anti-anthrax antibody, formulations thereof, and methods of use
US7673853B2 (en) 2006-10-12 2010-03-09 Cordell Eldred Ebeling Fencing section with adjustable fencing members
UY30776A1 (en) 2006-12-21 2008-07-03 Medarex Inc CD44 ANTIBODIES
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA3187687A1 (en) 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2186928A1 (en) 2008-11-14 2010-05-19 Enthone, Inc. Method for the post-treatment of metal layers
FR2945538B1 (en) 2009-05-12 2014-12-26 Sanofi Aventis HUMANIZED ANTIBODIES SPECIFIC TO THE PROTOFIBRILLARY FORM OF THE BETA-AMYLOID PEPTIDE.
TWI653333B (en) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 Cross-species specific PSMAxCD3 bispecific single chain antibody
EP3336225B1 (en) 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
US20130015055A1 (en) * 2011-07-11 2013-01-17 Hariharakeshava Sarpangala Hegde Dual plasma source systems and methods for reactive plasma deposition
WO2014074942A1 (en) * 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
WO2016064895A1 (en) 2014-10-20 2016-04-28 The Brigham And Women's Hospital, Inc. Targeting apolipoprotein e (apoe) in neurologic disease
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
US20190330335A1 (en) 2015-10-06 2019-10-31 Alector Llc Anti-trem2 antibodies and methods of use thereof
AU2017300040A1 (en) 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
JOP20190248A1 (en) 2017-04-21 2019-10-20 Amgen Inc Trem2 antigen binding proteins and uses thereof
DK3601358T5 (en) 2017-08-03 2024-09-02 Alector Llc ANTI-TREM2 ANTIBODIES AND METHODS OF USING THEREOF
WO2019055841A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
KR102860409B1 (en) 2017-12-12 2025-09-16 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 Anti-TREM2 antibodies and related methods

Also Published As

Publication number Publication date
WO2016023019A2 (en) 2016-02-11
WO2016023019A3 (en) 2016-07-28
EP4066859A1 (en) 2022-10-05
IL250115A0 (en) 2017-03-30
US20170240631A1 (en) 2017-08-24
AU2021202840A1 (en) 2021-06-03
US20190315858A1 (en) 2019-10-17
NZ729157A (en) 2024-08-30
MX2023000334A (en) 2023-02-09
EP3177322A4 (en) 2018-07-18
EA201790342A1 (en) 2017-07-31
US20230107639A1 (en) 2023-04-06
IL279606B (en) 2022-08-01
US20190010230A1 (en) 2019-01-10
SG10201913611QA (en) 2020-03-30
IL279606A (en) 2021-03-01
EP3177322A2 (en) 2017-06-14
JP7326135B2 (en) 2023-08-15
IL250115B (en) 2021-01-31
AU2021202840B2 (en) 2024-10-31
JP2017523814A (en) 2017-08-24
CA3090240A1 (en) 2016-02-11
JP7730936B2 (en) 2025-08-28
JP2020063268A (en) 2020-04-23
JP6669749B2 (en) 2020-03-18
CN107106679B (en) 2022-07-26
CN107106679A (en) 2017-08-29
CA2955086A1 (en) 2016-02-11
US11084875B2 (en) 2021-08-10
AU2015300787A1 (en) 2017-02-02
HK1243006A1 (en) 2018-07-06
JP2024073453A (en) 2024-05-29
MX2017001531A (en) 2017-05-15
NZ766877A (en) 2024-08-30
JP2022081543A (en) 2022-05-31

Similar Documents

Publication Publication Date Title
IL279606A (en) Anti-trem2 antibodies and methods of use thereof
IL259495A (en) Antibodies and methods of use thereof
IL251868B (en) Anti-tim3 antibodies and methods of use
ZA201703167B (en) Anti-cd79b antibodies and methods of use
IL254887A0 (en) Anti-sortilin antibodies and methods of use thereof
ZA201800315B (en) Anti-jagged1 antibodies and methods of use
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
IL248399A0 (en) Novel antii-rnf43 antibodies and methods of use
IL247754A0 (en) Anti-mcam antibodies and associated methods of use
ZA201701674B (en) Novel anti-mfi2 antibodies and methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of use
IL270793A (en) Anti-htra1 antibodies and methods of use thereof
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use